Antibody-Based Synthetic Cannabinoid Detection via ELISA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting synthetic cannabinoids, such as those based on GC-MS/LC-MS profiles, are inadequate for identifying new or modified active molecules quickly and efficiently, requiring resource-intensive chemical analytical studies due to minor molecular changes that evade detection.
Innovation Solution
Development of novel antibodies raised against specific immunogens that bind to synthetic cannabinoids and their metabolites, enabling rapid and economic detection and quantification using ELISA techniques, with cross-reactivity across related compounds, for use in both herbal therapeutics and in vitro patient samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If GC-MS/LC-MS analysis is used to detect synthetic cannabinoids, then detection accuracy is improved, but resource consumption and time required increase significantly
Solution Approach 1:
The patent replaces complex chemical analytical systems (GC-MS/LC-MS) with a biological recognition system (antibody-based immunoassay). The antibody specifically binds to CP synthetic cannabinoids and their metabolites, providing accurate detection through immunological recognition rather than chemical separation and mass spectrometry, thereby reducing resource consumption while maintaining detection accuracy.
Solution Approach 2:
The patent introduces an antibody as an intermediary that specifically recognizes and binds to CP synthetic cannabinoids and their metabolites. This antibody acts as a mediator between the target analytes and the detection system, enabling rapid and accurate detection through immunological assays without requiring complex chemical analytical procedures.
2Loss of information
If chemical analytical studies are conducted to characterize new synthetic cannabinoids, then structural identification is improved, but cost and time resources increase
Solution Approach 1:
The patent performs preliminary structural characterization by designing antibodies against specific immunogens that represent key structural features of CP synthetic cannabinoids. This preliminary action allows the antibody to recognize not only the original compounds but also novel analogs with similar structural characteristics, enabling rapid identification of new variants without extensive chemical analysis.
Solution Approach 2:
The patent creates a universal detection system where a single antibody can recognize multiple CP synthetic cannabinoids and their metabolites (including CP-47,497, CP-55,940, HU-210, HU-211, and their metabolites). This multi-functional antibody provides broad structural identification capability across different CP compounds, reducing the need for separate characterization studies for each new variant.
3Difficulty of detecting and measuring
If pre-derivatisation is performed for GC-MS analysis, then detection capability is improved, but procedural complexity increases
Solution Approach 1:
The patent replaces the mechanical/chemical derivatisation process with a biological recognition process. The antibody directly binds to the native or metabolized forms of CP synthetic cannabinoids without requiring chemical modification, thereby simplifying the procedure while maintaining or improving detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide a practical and rapid method for detecting and determining known and stealth synthetic cannabinoids, allowing for effective identification and quantification without the need for extensive chemical analysis, facilitating timely detection and regulation.
Implementation Method 1
an antibody which binds to an epitope of structure II
Implementation Method 2
where B/B0 is determined by measuring absorbance at 450nm
Data Source
Figure 1~2
Figure 3a~3b
Figure 4~5
AI summary
The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from immunogens enable said methods and kits.